Transient atrial fibrillation complicating acute inferior myocardial infarction: Implications for future risk of ischemic stroke

Chest

Volumn 132, Issue 1, 2007, Pages 44-49

  Siu, Chung Wah ^a   Jim, Man Hong ^a   Ho, Hee Hwa ^a   Miu, Raymond ^a   Lee, Stephen W L ^a   Lau, Chu Pak ^a   Tse, Hung Fat ^a,b  

^a QUEEN MARY HOSPITAL   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Atrial fibrillation; Myocardial infarction; Stroke

Indexed keywords

ANTITHROMBOCYTIC AGENT;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; DISEASE ASSOCIATION; FEMALE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SINUS RHYTHM; ST SEGMENT ELEVATION;

EID: 34447572670     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.06-2733     Document Type: Article

References (25)

1. Wong CK, White HD, Wilcox RG, et al. Significance of atrial fibrillation during acute myocardial infarction, and its current management: insights from the GUSTO-3 trial. Card Electrophysiol Rev 2003; 7:201-207
2. Wong CK, White HD, Wilcox RG, et al. New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. Am Heart J 2000; 140: 878-885
3. Crenshaw BS, Ward SR, Granger CB, et al. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience; Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol 1997; 30: 406-413
4. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343:687-691
5. European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342:1255-1262
6. Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991; 18:349-355
7. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323:1505-1511
8. Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet 1989; 1:175-179
9. Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002; 347: 969-974
10. Khurram Z, Chou E, Minutello R, et al. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. J Invasive Cardiol 2006; 18:162-164
11. Tanne D, Reicher-Reiss H, Boyko V, et al. Stroke risk after anterior wall acute myocardial infarction: SPRINT Study Group; Secondary Prevention Reinfarction Israeli Nifedipine Trial. Am J Cardiol 1995; 76:825-826
12. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004; 110:e82-e292
13. Van de Werf F, Ardissino D, Betriu A, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003; 24:28-66
14. Pedersen OD, Bagger H, Kober L, et al. The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction: TRACE Study group; TRAndolapril Cardiac Evalution. Eur Heart J 1999; 20:748-754
15. Lehto M, Snapinn S, Dickstein K, et al. Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience. Eur Heart J 2005; 26:350-356
16. Flaker GC, Fletcher KA, Rothbart RM, et al. Clinical and echocardiographic features of intermittent atrial fibrillation that predict recurrent atrial fibrillation: Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Am J Cardiol 1995; 76:355-358
17. Hart RG, Pearce LA, Rothbart RM, et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy: Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 2000; 35:183-187
18. Stenestrand U, Lindback J, Wallentin L. Anticoagulation therapy in atrial fibrillation in combination with acute myocardial infarction influences long-term outcome: a prospective cohort study from the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-IIIA). Circulation 2005; 112:3225-3231
19. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: executive summary; a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006; 48:854-906
20. National Collaborating Centre for Chronic Conditions. Atrial fibrillation: national clinical guideline for management in primary and secondary care. London, UK: Royal College of Physicians, 2006
21. Husted SE, Ziegler BK, Kher A. Long-term anticoagulant therapy in patients with coronary artery disease. Eur Heart J 2006; 27:913-919
22. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antifhrombotic-drug regimens after coronary-artery stenting: Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339:1665-1671
23. Lip GY, Karpha M. Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: the need for consensus and a management guideline. Chest 2006; 130:1823-1827
24. Orford JL, Fasseas P, Melby S, et al. Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J 2004; 147:463-467
25. Rubboli A, Colletta M, Sangiorgio P, et al. Antithrombotic strategies in patients with an indication for long-term anticoagulation undergoing coronary artery stenting: safety and efficacy data from a single center. Ital Heart J 2004; 5:919-925